Ticlopidine nonclinical toxicology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:


==Nonclinical Toxicology==
==Nonclinical Toxicology==
:*'''Carcinogenesis''':*'''Mutagenesis''':*'''Impairment of Fertility'''
:*'''Carcinogenesis'''
:*'''Mutagenesis'''
:*'''Impairment of Fertility'''


In a 2-year oral carcinogenicity study in rats, ticlopidine at daily doses of up to 100 mg/kg (610 mg/m2 ) was not tumorigenic. For a 70-kg person (1.73 m2 body surface area) the dose represents 14 times the recommended clinical dose on a mg/kg basis and two times the clinical dose on body surface area basis. In a 78-week oral carcinogenicity study in mice, ticlopidine at daily doses up to 275 mg/kg (1180 mg/m2 ) was not tumorigenic. The dose represents 40 times the recommended clinical dose on a mg/kg basis and four times the clinical dose on body surface area basis.
In a 2-year oral carcinogenicity study in rats, ticlopidine at daily doses of up to 100 mg/kg (610 mg/m2 ) was not tumorigenic. For a 70-kg person (1.73 m2 body surface area) the dose represents 14 times the recommended clinical dose on a mg/kg basis and two times the clinical dose on body surface area basis. In a 78-week oral carcinogenicity study in mice, ticlopidine at daily doses up to 275 mg/kg (1180 mg/m2 ) was not tumorigenic. The dose represents 40 times the recommended clinical dose on a mg/kg basis and four times the clinical dose on body surface area basis.


Ticlopidine was not mutagenic in vitro in the Ames test, the rat hepatocyte DNA-repair assay, or the Chinese-hamster fibroblast chromosomal aberration test; or in vivo in the mouse spermatozoid morphology test, the Chinese-hamster micronucleus test, or the Chinese-hamster bone-marrow-cell sister-chromatid exchange test. Ticlopidine was found to have no effect on fertility of male and female rats at oral doses up to 400 mg/kg/day.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = TICLOPIDINE HYDROCHLORIDE TABLET, FILM COATED [APOTEX CORP.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=707127cb-cdcd-81b0-274d-3c11fefa6824 | publisher =  | date =  | accessdate = }}</ref>
Ticlopidine was not mutagenic in vitro in the Ames test, the rat hepatocyte DNA-repair assay, or the Chinese-hamster fibroblast chromosomal aberration test; or in vivo in the mouse spermatozoid morphology test, the Chinese-hamster micronucleus test, or the Chinese-hamster bone-marrow-cell sister-chromatid exchange test. Ticlopidine was found to have no effect on fertility of male and female rats at oral doses up to 400 mg/kg/day.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = TICLOPIDINE HYDROCHLORIDE TABLET, FILM COATED [APOTEX CORP.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=707127cb-cdcd-81b0-274d-3c11fefa6824 | publisher =  | date =  | accessdate = }}</ref>
==References==
==References==
{{Reflist}}
{{Reflist}}

Revision as of 16:56, 6 February 2014

Ticlopidine
Ticlopidine® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Ticlopidine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Nonclinical Toxicology

  • Carcinogenesis
  • Mutagenesis
  • Impairment of Fertility

In a 2-year oral carcinogenicity study in rats, ticlopidine at daily doses of up to 100 mg/kg (610 mg/m2 ) was not tumorigenic. For a 70-kg person (1.73 m2 body surface area) the dose represents 14 times the recommended clinical dose on a mg/kg basis and two times the clinical dose on body surface area basis. In a 78-week oral carcinogenicity study in mice, ticlopidine at daily doses up to 275 mg/kg (1180 mg/m2 ) was not tumorigenic. The dose represents 40 times the recommended clinical dose on a mg/kg basis and four times the clinical dose on body surface area basis.

Ticlopidine was not mutagenic in vitro in the Ames test, the rat hepatocyte DNA-repair assay, or the Chinese-hamster fibroblast chromosomal aberration test; or in vivo in the mouse spermatozoid morphology test, the Chinese-hamster micronucleus test, or the Chinese-hamster bone-marrow-cell sister-chromatid exchange test. Ticlopidine was found to have no effect on fertility of male and female rats at oral doses up to 400 mg/kg/day.[1]

References

  1. "TICLOPIDINE HYDROCHLORIDE TABLET, FILM COATED [APOTEX CORP.]".

Adapted from the FDA Package Insert.